Effects of Low Protein Diet Supplemented With Ketoanalogues on Preservation of Kidney Function in Incremental Dialysis

The Effects of Low Protein Diet Supplemented With Ketoanalogues on Preservation of Residual Kidney Function Among Patients Undergoing Incremental Dialysis

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05030168

Enrollment

Registered

2021-09-01

Start date

2021-12-31

Completion date

2024-03-31

Last updated

2021-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Function, Hemodialysis

Brief summary

The investigators hypothesized that combination of incremental hemodialysis and ketoanologues will better preserve residual kidney function and maintenance of nutritional status among the incident ESRD patients during the early initiation of chronic dialysis. This hypothesis has been a new concept of chronic hemodialysis initiation for End stage renal disease (ESRD) patients

Detailed description

The investigators plan to conduct the first randomized Phase IIA clinical trial to investigate the efficacy of incremental hemodialysis and moderately low protein diet combined with ketoanologues supplementation on preservation of residual kidney function, inflammatory status and nutritional parameters among incident chronic dialysis patients

Interventions

DRUGKetosteril

ketoanalogues of essential amino acid

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years at screening * Stable CKD stage 5 not yet on dialysis with residual kidney function 5-10 ml/min/1.73m2 by CKD-EPI equation * Urine output ≥ 800 ml/day * Willing to participate in the study and can provide inform consent

Exclusion criteria

* Rapid glomerular filtration rate (GFR) progression defined as a decline of eGFR \>10 ml/min/1.73m2 by CKD-EPI equation in the prior 6 months before enrollment * Presence of wasting diseases, cancer cachexia, tuberculosis, AIDS wasting syndrome * Other active infection/inflammation determined by CRP \>10 mg/L * Severe gastrointestinal problem: persistent nausea/vomiting, dysphagia, chronic diarrhea, severe malabsorption * Conditions at baseline requiring withdrawal from the study including severe protein energy wasting by SGA and MIS score, prior kidney transplantation with immunosuppressive agents or other serious medical conditions. * Pregnancy * Uncontrolled hypercalcemia (persistent serum Ca ≥10.5 mg/dl) * BMI ≥ 35 kg/m2 * Hypersensitivity to the active substances or to any of the excipients of Ketosteril * Disturbed amino acid metabolism

Design outcomes

Primary

Measure	Time frame	Description
residual renal function	12 months	To demonstrate superiority effect of incremental hemodialysis (HD) protocol (initiate with once-weekly hemodialysis) plus ketoanalogues-supplemented low-protein diet during non-dialysis days over the standard HD protocol (initiate with twice weekly hemodialysis) on preservation of residual renal function (renal urea clearance) at 12 months.

Secondary

Measure	Time frame	Description
visceral protein	12 months	To compare serum albumin levels between the two treatment groups over 12 months.
structural protein	12 months	To compare muscle mass between the two treatment groups over 12 months.
muscle function	12 months	To compare muscle strength between the two treatment groups over 12 months.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026